Cerlapirdine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cerlapirdine
Cerlapirdine structure.png
Systematic (IUPAC) name
N,N-dimethyl-3-{[3-(naphthalen-1-ylsulfonyl)-2H-indazol-5-yl]oxy}propan-1-amine
Clinical data
Legal status
  • Non-regulated
Identifiers
CAS number 925448-93-7
925447-04-7 (hydrochloride)
ATC code None
PubChem CID 16071605
ChemSpider 17231095
KEGG D10099 YesY
ChEMBL CHEMBL2103880
Chemical data
Formula C22H23N3O3S 
Mol. mass 409.501 g/mol

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which is under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.[1] As of 2011, it is in phase II clinical trials, and has demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events.[2] It exerts its effects by acting as a selective 5-HT6 receptor antagonist.[1]

See also[edit]

References[edit]

  1. ^ a b Codony X, Vela JM, Ramírez MJ (February 2011). "5-HT(6) receptor and cognition". Current Opinion in Pharmacology 11 (1): 94–100. doi:10.1016/j.coph.2011.01.004. PMID 21330210. 
  2. ^ Franco Borsini (2011). International review of neurobiology: Pharmacology of 5-HT6 receptors. Part 2. Academic Press. p. 5. ISBN 978-0-12-385902-0. Retrieved 25 October 2011.